TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05039944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: In Arm_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: In Arm_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: In Arm_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: In Arm_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administration by intravenous infusion, 180 mg/m2 Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administration by intravenous infusion, 180 mg/m2 Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: FOLFIRI is administered intravenously at the standard dose recommended by the guidelines(Q2W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX Protocol
Description: FOLFOX is administered intravenously at the standard dose recommended by the guidelines(Q2W).
Study: NCT05893381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA I&T
Description: The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiotherapy
Description: Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
Study: NCT05916469

Intervention type: DRUG
Intervention: Levonorgestrel Intrauterine System
Description: 52 mg levonorgestrel intrauterine system

Intervention type: DRUG
Intervention: Levonorgestrel Intrauterine System
Description: 52 mg levonorgestrel intrauterine system
Study: NCT04049539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT05916469

Intervention type: DRUG
Intervention: Norethindrone Acetate
Description: norethindrone acetate 5 mg daily
Study: NCT06341816

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VEXUS score
Description: The VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VEXUS score
Description: The VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.
Study: NCT06520761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injectable platelet rich fibrin
Description: blood sample obtained from the participant, centrifuged at 700 rpm to produce injectable platelet rich fibrin, this will be injected around the upper canine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level LASER
Description: Diode LASER device is used to apply Low Level LASER around the upper canine
Study: NCT05502406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft tissue Mobilization
Description: Using a C shaped IASTM tool gentle horizontal stroking at an angle of 45 degree will be given over the cervicodorsal fascia
Study: NCT06341816

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NGAL
Description: Neutrophil gelatinase-associated lipocalin

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NGAL
Description: Neutrophil gelatinase-associated lipocalin
Study: NCT05439681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400
Description: medium cut off (MCO) membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400
Description: medium cut off (MCO) membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400
Description: medium cut off (MCO) membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400
Description: medium cut off (MCO) membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX 10
Description: low-flux membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX 10
Description: low-flux membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX 10
Description: low-flux membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX 10
Description: low-flux membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX CorDiax 800
Description: high-flux membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX CorDiax 800
Description: high-flux membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX CorDiax 800
Description: high-flux membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX CorDiax 800
Description: high-flux membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HDF
Description: hemodiafiltration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HDF
Description: hemodiafiltration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HDF
Description: hemodiafiltration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HDF
Description: hemodiafiltration
Study: NCT04970615

Intervention type: DEVICE
Intervention: Three-dimensional printed model
Description: Three-dimensional printers are able to print physical objects in real size and colours. As a respresentative of the real tumor, a personalized three-dimensional model enables visualization of the patient-specific tumor and eloquent areas.
Study: NCT05469672

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy
Description: For LLLT, laser treatment will be applied using gallium-aluminum-arsenide (GaAIAs, infrared laser) diode laser (Chattanooga, Mexico, USA) at a wavelength of 904 nm, output power of 240 Mw and a frequency of 5000 Hz. The spot area is about 0.5 cm2. A total of 9 points will irradiated along the glenohumeral joint, with a power density of 3 j/cm2 at each point. The application time was 50 seconds to each point. The total dose per shoulder was 27 J per treatment. Three sessions of LILT therapy per week will administered over a three-week period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy
Description: For LLLT, laser treatment will be applied using gallium-aluminum-arsenide (GaAIAs, infrared laser) diode laser (Chattanooga, Mexico, USA) at a wavelength of 904 nm, output power of 240 Mw and a frequency of 5000 Hz. The spot area is about 0.5 cm2. A total of 9 points will irradiated along the glenohumeral joint, with a power density of 3 j/cm2 at each point. The application time was 50 seconds to each point. The total dose per shoulder was 27 J per treatment. Three sessions of LILT therapy per week will administered over a three-week period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity laser therapy
Description: HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the shoulder area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first three sessions consisted of a 75-second intermittent phase analgesic effect at 8 W and 10 J/cm2 for a total energy of 100 J. The following six sessions consisted of a continuous 30-second bio stimulating effect with a dosage of 12 W 120 J/cm2. Over the course of three weeks, nine treatment sessions of HILT will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity laser therapy
Description: HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the shoulder area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first three sessions consisted of a 75-second intermittent phase analgesic effect at 8 W and 10 J/cm2 for a total energy of 100 J. The following six sessions consisted of a continuous 30-second bio stimulating effect with a dosage of 12 W 120 J/cm2. Over the course of three weeks, nine treatment sessions of HILT will be given.
Study: NCT04632225

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engensis
Description: Lyophilized biologic to be reconstituted containing Engensis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injectable liquid
Study: NCT05502406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Myofascial Release
Description: Participants will receive myofascial release through velvet glove technique on upper trapezius and sternocleidomastoid muscle using four strokes in the following fashion:~* Begin superior to the clavicle with a loose fist and move the back of the hand over the upper trapezius, fastening the tissue and bringing it over the table.~* The next stroke addresses the curve of the neck, again hooking the tissue while moving the bak of your fist towards the table.~The last stroke goes over the entire cervical spine hooking over the sternocleidomastoid muscle bringing it into myofascial release. Stay away from the carotid pulse, and incase a pulse is felt, do not apply pressure and reposition your hand
Study: NCT04945291

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: New way of counting calories using the hands
Description: The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New way of counting calories using the hands
Description: The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile applications
Description: the participant will use a mobile application to log their calories
Study: NCT05717569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: o Fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. It is a promising non-invasive method for detection of cirrhosis in patients with chronic liver disease. Therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . In our study the investigators will assess liver fibrosis before and after vitamin D therapy using fibroscan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: o Fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. It is a promising non-invasive method for detection of cirrhosis in patients with chronic liver disease. Therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . In our study the investigators will assess liver fibrosis before and after vitamin D therapy using fibroscan.
Study: NCT05361863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic brackets
Description: Interventions involving orthodontic brackets of different slot sizes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic brackets
Description: Interventions involving orthodontic brackets of different slot sizes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic brackets
Description: Interventions involving orthodontic brackets of different slot sizes
Study: NCT05777135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer Lactate prior to surgery and Propofol
Description: Ringer Lactate prior to surgery and Propofol dose requirement for induction of anaesthesia will be noted
Study: NCT05236257

Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Pediatric patients with IFS harboring an NTRK gene fusion.

Intervention type: DRUG
Intervention: Standard of Care
Description: Standard of care for the patients from the eligible external cohorts.
Study: NCT04945291

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile applications
Description: the participant will use a mobile application to log their calories

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile applications
Description: the participant will use a mobile application to log their calories
Study: NCT05296239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SimpleC Wellness Platform with Social Robot Interaction
Description: Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia.
Study: NCT04203004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HOPE with cytokine filtration by CytoSorb
Description: Cytokine filtration during HOPE
Study: NCT06671106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: toothbrushing
Description: manual toothbrush (meridol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: toothbrushing
Description: manual toothbrush (meridol)

Intervention type: OTHER
Group type: OTHER
Intervention: toothbrushing
Description: manual toothbrush (meridol)
Study: NCT06447870

Intervention type: DRUG
Intervention: biologic therapy(eg:IFX,ADA,UST,VDZ)
Description: The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.

Intervention type: DRUG
Intervention: biologic therapy(eg:IFX,ADA,UST,VDZ)
Description: The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.
Study: NCT06379854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest physiotherapy
Description: Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trunk rotation exercises,deep diaphragmatic also chest physiotherapy
Description: Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy~Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Deep Diaphragmatic Breathing Exercise F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy TLFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises TFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises
Study: NCT06522763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets.
Description: The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ
Description: The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
Study: NCT06515886

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Examination
Description: Clinical examination of a dental implant

Intervention type: PROCEDURE
Intervention: Peri-implant crevicular fluid
Description: Collection of a sample of peri-implant crevicular fluid
Study: NCT05502809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep-frozen platelets
Description: Cryopreserved platelets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deep-frozen platelets
Description: Cryopreserved platelets
Study: NCT05718921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose A on low body surface area
Description: Part A: Single topical dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose A on middle body surface area
Description: Part A: Single topical dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose A on high body surface area
Description: Part A: Single topical dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose B on low body surface area
Description: Part A: Single topical dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose B on middle body surface area
Description: Part A: Single topical dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose B on high body surface area
Description: Part A: Single topical dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on low body surface area
Description: Part A: Single topical dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on middle body surface area
Description: Part A: Single topical dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on high body surface area
Description: Part A: Single topical dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose A on high body surface area twice daily
Description: Part B: Multiple topical dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose B on high body surface area twice daily
Description: Part B: Multiple topical dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on high body surface area twice daily
Description: Part B: Multiple topical dose
Study: NCT05056311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid Website
Description: The (private) decision aid website contains information in text, graphic, and video form about hypospadias and considerations for choosing surgery and no surgery.
Study: NCT05392543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brunnstrom movement therapy.
Description: Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session.
Study: NCT06055452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Each participant in the empagliflozin treatment group takes a daily dose of 10mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant in the placebo group takes matching placebo.